ImmunoGen, Inc. (NASDAQ:IMGN) traded with the volume of 1.21 Million in the previous trading session. The Stock opened its session at $0 and closed at $2.51 by showing decrease of -0.4 percent. ImmunoGen, Inc. has 1 year price target of $4.57. The stock gained a consensus recommendation of 2.66 on Zacks Investment Research where the scale runs from 1 to 5, 1 representing Strong buy and 5 showing Strong Sell. The company reported its last quarter on Sep 16.
On Sep 16 ImmunoGen, Inc. (NASDAQ:IMGN) reported its EPS in the last quarter as $-0.51/Share lagging the analyst estimate of $-0.38/Share by the difference of $-0.13. This showed the surprise of -34.2% in the last quarter earnings. For the Current Quarter, 4 analysts are projecting the mean EPS to be $-0.37/share. According to their observations and findings, the stock could provide a high EPS of $-0.17/share and a Low EPS of $-0.47/share.
The 6 analysts offering 12-month price forecasts for ImmunoGen Inc have a median target of 3.75, with a high estimate of 6.00 and a low estimate of 2.00. The median estimate represents a +49.40% increase from the last price of 2.51. (CNN MONEY)
Many Analysts provided their foresight on Revenue Estimates of ImmunoGen, Inc. where they believe that the company has the potential to earn average revenue of $18.1 Million for the current quarter. According to their predictions High & Low revenue estimates are 22 Million and 7.58 Million respectively.
ImmunoGen, Inc. (NASDAQ:IMGN) topped its 52-week high price of $10.43 on Jan 13, 2016 and 52-Week Low Price of $1.51 on Nov 3, 2016. The Stock currently has the market capitalization of $218.63 Million, P/E (price to earnings ttm) of 0 and Weekly volatility of 12.61% and monthly volatility of 9.85% respectively.
ImmunoGen, Inc. Gross Margin percentage stands at 0% while its Operating Margin for trailing twelve month is 0 percent and Profit margin (ttm) is 0 Percent. The stock is currently moving above its 20-Day Simple Moving Average of 31.87% with the 50-Day Simple Moving Average of 31.87 percent. Currently, the company has SMA200 (200-day simple moving average) of -33.81 Percent. The Stock has YTD (year to date) performance of 23.04 percent.
Many research firms have provided their ratings on ImmunoGen, Inc. (NASDAQ:IMGN) where RBC Capital Mkts provided Sector Perform rating on the stock on 29-Apr-16. Other firms include Jefferies giving Buy rating on 25-Nov-15.
The latest Insider trade was made on 14 Dec 2016 where Goldberg (Mark A. M.D.) Director did a transaction type “Buy” in which 20000 shares were traded at a price of $1.8. Another insider trade includes Chief Executive Officer Enyedy (Mark J) who also initiated a transaction in which 25000 shares were traded on 7 Nov 2016 as “Buy”.
ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company’s product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.